Skip to main content
SpringerLink
Log in

GH-releasing peptide (GHRP-6)-induced ACTH release in patients with Addison’s disease: Effect of glucocorticoid withdrawal

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

GH releasing peptide (GHRP-6) is a synthetic hexapeptide with potent GH releasing activity both in man and in animals. This peptide is also able to stimulate ACTH and cortisol (F) release. It has been suggested that the ACTH responsiveness to GHRP-6 is modulated by circulating glucocorticoid levels. To further clarify this hypothesis, we studied the effect of GHRP-6 (1ug/kg, iv) on ACTH and F release in patients with Addison’s disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal. Seven controls were also submitted to a single GHRP-6 test. In control subjects, ACTH values (pmol/l; mean±SE) increased from 2.9±0.8 to 4.7±1.4 (peak). AUC (pmol.min/l) values were 170.3±48.8. F (nmol/l) values increased from 257.0±42.9 to 367.0±50.8. In patients with Addison’s disease there was an increase in ACTH levels from 38.1±17.1 to 174.9±79.4 after GHRP-6 administration. AUC values were 5490.4±2269.1. After 72 h withdrawal of glucocorticoid, there was an increase in basal ACTH values (191.2±97.3), and a trend toward an increase in ACTH levels after GHRP-6 (p=0.053). Patients with Addison’s disease on therapy showed a significantly higher ACTH response to GHRP-6 when compared to controls. Our results show that in patients with Addison’s disease on replacement there is an increased ACTH release after GHRP-6 administration, compared to controls. After 72 h glucocorticoid withdrawal, this enhanced responsiveness is not maintained. Our data suggest that circulating glucocorticoids modulate GHRP-6-induced ACTH release and that multiple mechanisms may be involved in this process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bowers C.Y., Momany F., Reynolds G.A., Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114: 1537–1545.

    Article  PubMed  CAS  Google Scholar 

  2. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormonereleasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.

    Article  PubMed  CAS  Google Scholar 

  3. Smith, R.G., Van der Ploeg L.H., Howard A.D. et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 1997, 18: 621–645.

    Article  PubMed  CAS  Google Scholar 

  4. Howard, A.D., Feighner S.D., Cully, D.F. et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–977.

    Article  PubMed  CAS  Google Scholar 

  5. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656–660.

    Article  PubMed  CAS  Google Scholar 

  6. Bowers C.Y., Reynolds G.A., Durham D., Barrera C.M., Pezzoli S.S., Thorner M.O. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J. Clin. Endocrinol. Metab. 1990, 70: 975–982.

    Article  PubMed  CAS  Google Scholar 

  7. Frieboes R., Murck H., Maier P., Schier T., Holsboer F., Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995, 61: 584–589.

    Article  PubMed  CAS  Google Scholar 

  8. Smith R.G., Cheng K., Schoen W.R. et al. A non-peptidyl GH secretagogue. Science 1993, 260: 1640–1643.

    Article  PubMed  CAS  Google Scholar 

  9. Elias K.A., Ingle G.S., Bunnier J.P. et al. In vitro characterization of four novel classes of growth hormone releasing peptide. Endocrinology 1995, 136: 5694–5699.

    PubMed  CAS  Google Scholar 

  10. Shimon I., Yan X., Melmed S. Human fetal pituitary expresses functional growth hormone releasing peptide receptors. J. Clin. Endocrinol. Metab. 1998, 83: 174–178.

    PubMed  CAS  Google Scholar 

  11. Hickey G., Drisko J,. Faidley T., et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J. Endocrinol. 1996, 148: 371–380.

    Article  PubMed  CAS  Google Scholar 

  12. Schleim K.D., Jacks T., Cunningham P., Feeney W., Frazier R.G., Hickey G. Increases in circulating insulin like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation. Endocrinology 1999, 140: 1552–1558.

    PubMed  CAS  Google Scholar 

  13. Thomas G., Fairhall K., Robinson I. Activation of the hypothalamo- pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 1997, 138: 1585–1591.

    Article  PubMed  CAS  Google Scholar 

  14. Arvat E., Maccagno B., Ramunni J., et al. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans. Neuroendocrinology 1997, 66: 432–438.

    Article  PubMed  CAS  Google Scholar 

  15. Arvat E., Ramunni J., Bellone J., et al. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. Eur. J. Endocrinol. 1997, 137: 635–642.

    Article  PubMed  CAS  Google Scholar 

  16. Arvat E., Maccagno B., Ramunni J., et al. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans. Neuroendocrinology 1998, 67: 310–316.

    Article  PubMed  CAS  Google Scholar 

  17. Fuxe K., Cintra A., Tanganelli S., et al. Integration of humoral and neuronal signals in neuroendocrine regulation. Focus on interaction of glucocorticoids with central neuropeptide and monoamine neurotransmission. In: Casanueva F.F., Dieguez C. (Eds.), Recent Advances in Basic and Clinical Neuroendocrinology. Excerpta Medica, 1989, p.109.

    Google Scholar 

  18. Thomas G.B., Bennet P.A., Carmignac D.F., Robinson C.A.F. Glucocorticoid regulation of growth hormone (GH) secretagogue-induced growth responses and GH secretagogue receptor expression in the rat. Growth Horm. IGF Res. 2000, 10: 45–52.

    Article  PubMed  CAS  Google Scholar 

  19. Ghigo E., Arvat E., Ramunni J., et al. Adrenocorticotropinand cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing’s syndrome. J. Clin. Endocrinol. Metab. 1997, 82: 2439–2444.

    PubMed  CAS  Google Scholar 

  20. Arvat E., Ramunni J., Giordano R. et al. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing’s disease. J. Endocrinol. Invest. 1999, 22: 23–28.

    Article  PubMed  CAS  Google Scholar 

  21. Arvat E., Ramunni J., Maccagno B. et al. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison’s disease. Neuroendocrinology 1999, 70: 200–206.

    Article  PubMed  CAS  Google Scholar 

  22. Korbonits M., Kaltsas G., Perry L., et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary- adrenal axis via arginine vasopressin. J. Clin. Endocrinol. Metab. 1999, 84: 2489–2495.

    Article  PubMed  CAS  Google Scholar 

  23. Dickson S.L., Leng G., Robinson I.C.A.F. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience 1993, 53: 303–306.

    Article  PubMed  CAS  Google Scholar 

  24. Dickson S.L., Luckman S.M. Induction of c-fos mRNA in neuropeptide-Y and growth hormone-releasing hormone neurones in the rat arcuate nucleus following systemic injection of the growth hormone secretagogue, GHRP-6. Endocrinology 1997, 138: 771–777.

    PubMed  CAS  Google Scholar 

  25. Korbonits M., Little J.A., Forsling M.L., et al. The effect of growth hormone secretagogue and neuropeptide-Y on hypothalamic hormone release from acute rat hypothalamic explants. Neuroendocrinology 1999, 11: 521–528.

    Article  CAS  Google Scholar 

  26. Scott R.S., Donald R.A., Espiner E.A. Plasma ACTH and cortisol profiles in addisonian patients receiving conventional substitution therapy. Clin. Endocrinol. (Oxf) 1978, 9: 571–576.

    Article  CAS  Google Scholar 

  27. Feek C.M., Ratcliffe J.G., Seth J., et al. Patterns of plasma cortisol and ACTH concentrations in patients with Addison’s disease treated with conventional corticosteroid replacement. Clin. Endocrinol. (Oxf) 1981, 14: 451–458.

    Article  CAS  Google Scholar 

  28. Hermus A.R.M.M., Pieters G.F.F.M., Pesman G.J., Smals A.G.H., Benraad T.J., Kloppenborg P.W.C. ACTH and cortisol responses to ovine corticotrophin-releasing factor in patients with primary and secondary adrenal failure. Clin. Endocrinol. (Oxf) 1985, 22: 761–769.

    Article  CAS  Google Scholar 

  29. Pinto A.C.A.R., Silva M.R.D., Martins M.R.A., Brunner E., Lengyel A.M.J. Effects of short term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing peptide-6: Studies in normal men and in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 2000, 85: 1540–1544.

    PubMed  CAS  Google Scholar 

  30. Tamura H., Kamegai J., Sugihara H., Kineman R.D., Frohman L.A., Wakabayashi I. Glucocorticoids regulate pituitary growth hormone secretagogue receptor gene expression. J. Neuroendocrinol. 2000, 12: 481–485.

    Article  PubMed  CAS  Google Scholar 

  31. Bochicchio D., Ambrosi B., Faglia G. Loperamide, an opiate analog, differently modifies the adrenocorticotropin responses to corticotropin-releasing hormone and lysine vasopressin in patients with Addison’s disease. Neuroendocrinology 1988, 48: 611–614.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Universidade Federal de São Paulo, UNIFESP/EPM, Caixa Postal: 20.266, São Paulo, SP, 04034-970, Brazil

    Manoel Ricardo Alves Martins, A-C. A. R. Pinto, E. Brunner, M. R. D. Silva & A-M. J. Lengyel

Authors
  1. Manoel Ricardo Alves Martins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A-C. A. R. Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. R. D. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A-M. J. Lengyel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manoel Ricardo Alves Martins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martins, M.R.A., Pinto, AC.A.R., Brunner, E. et al. GH-releasing peptide (GHRP-6)-induced ACTH release in patients with Addison’s disease: Effect of glucocorticoid withdrawal. J Endocrinol Invest 26, 143–147 (2003). https://doi.org/10.1007/BF03345143

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345143

Key-words

Search

Navigation